Overview:
Platelet rich plasma (PRP) is a product that contains large number of platelets in a small plasma volume. PRP works as a fibrin tissue adhesive with tissue sealing and hemostatic characteristics. PRP differs from platelet-poor tissue and fibrin glue because PRP provides a unique ability to augment wound healing process and osteogenesis. PRP functions as a safe, biocompatible prompt hemostatic agent and fast-tracks epidermal, epithelial and endothelial regeneration. PRP enhances collagen synthesis, encourages angiogenesis, reduces dermal scarring, augments soft tissue healing and reverses inhibition of glucocorticoid would healing. High concentration of leukocyte in PRP offers additional antimicrobial effect.
PRP offers a wide range of clinical healing uses in otolaryngology, general surgery, cosmetic surgery and aesthetics, burn and would healing, cardiovascular surgery, oral and maxillofacial surgical procedures and others. PRP has proven effectiveness in treating chronic non-healing wounds and has been adopted as antiangiogenic agent. In surgical procedures, PRP reduces the risk of postoperative and preoperative bleeding both at donor and recipient sites; it augments soft tissue healing and facilitates stability to grafted tissue at recipient site owing to its adhesive and cohesive properties.
The global platelet rich plasma market is segmented on the following bases:
1. Type
a. Pure-Platelet Rich Plasma (P-PRP)
b. Leukocyte-Platelet Rich Plasma (L-PRP)
c. Leukocyte-Platelet Rich Fibrin (L-PRF)
2. Origin
a. Allogeneic
b. Autologous
c. Homologous
3. Clinical Applications
a. General Surgery
b. Neurosurgery
c. Cosmetic Surgery and Aesthetics
d. Orthopedic and Spinal Surgery
e. Others (Otorhinolaryngology-Head and Neck Surgery, Oral and Maxillofacial Surgery, Periodontal Surgery, Urology, Cardiothoracic Surgery, etc.)
4. Geography
a. North America
i. US
ii. Canada
b. Europe
i. UK
ii. Germany
iii. Rest of Europe
c. Asia Pacific
i. Japan
ii. China
iii. Rest of APAC
d. Latin America
e. Middle East and Africa
Key players identified for platelet rich plasma market include but are not limited to:
Arthrex, Inc., Arteriocyte Medical Systems, Inc., DePuy Synthes, Inc., Biomet, Inc., Cesca Therapeutics, Inc., Dr. PRP America LLC., EmCyte Corporation, AdiStem Ltd., Exactech, Inc., Nuo Therapeutics, Inc., Regen Lab SA, Harvest Technologies Corp. and several others
This report offers:
- An overview of the global markets for platelet rich plasma
- Market trends assessment for the period 2013-2023, with historical information for 2013 & 2014, and projections through 2023, with respective CAGRS during 2016-2023
- Qualitative assessment tools such as market drivers, challenges and future prospects, major commercial events, etc.
- Market competition scrutiny tools such as market share assessment, attractive investment proposition and others
- Focus on each level of market segmentation based on product approvals, launch, and current and anticipated market dynamics
- A general overview of the industry structure
- Company profiles highlighting key information about the major players operating in the platelet rich plasma market
